Press Releases
B52s ROCKER AFFECTED
BY GLAUCOMA CALLS NEW REVOLUTIONARY TREATMENT "MUSIC TO HIS
EYES"
CONTACT: Silvana Rodriguez 561/750-9800 x 21
E-mail: srodriguez@transmediagroup.com
FOR IMMEDIATE RELEASE:
NEW YORK, NY, February 22, 2001 - Fred Schneider, singer
with the rock band The B52s which stormed the charts
with the hit single, 'Love Shack' revealed today that he is
among the nearly 70 million people worldwide affected by Glaucoma
but feels there may be a bright note in his future with a
new treatment.
Called Pneumatic Trabeculoplasty (PNT™), this revolutionary
non-invasive treatment of glaucoma designed by Coronado Industries
(OTC:BB CDIK) lowers intraocular pressure in patients undergoing
treatment.
Schneider called his recent treatment using the PNT device
"music to his eyes." "The PNT device lowered the intraocular
pressure behind my eye and I am hopeful that it might be the
answer hoped for by millions who are affected by glaucoma,"
Schneider said.
John T. LiVecchi, MD, who performed the procedure at the
Northeastern Eye Institute in Scranton, Pennsylvania, said,
"The Pneumatic Trabeculoplasty procedure presents glaucoma
patients with a completely revolutionary way to treat it.
PNT reduces and in some cases eliminates the need for any
other method of treatment."
"We couldn't be more pleased with the results Mr. Schneider
has had with the PNT treatment," noted Richard Smith, CEO
of Coronado Industries, Inc.
The device, designed to lower intraocular pressure associated
with glaucoma, is currently undergoing clinical testing in
the U.S. Coronado recently signed an agreement with Novartis
(NYSE: NVS) granting them an exclusive option for global licensing
and distribution rights to Coronado's PNT equipment and non-invasive
treatment.
Coronado's Clinical Studies Director Dr. Leo Bores, who also
heads the Company's FDA compliance division, has been invited
to Rome where he will present to a panel of Italian ophthalmologists
the effectiveness of the device as a non-invasive treatment
of glaucoma. Dr. Bores will also travel to Kenya where he's
been invited by the government to undertake a similar demonstration
of Coronado's Pneumatic Trabeculoplasty in that country.
As part of Coronado's agreement with Novartis, Dr. Bores
is assisting them in its due diligence testing of the device
by instructing ophthalmologists and members of health care
systems worldwide on the treatment and use of PNT.
Forward-looking statements in this release are made pursuant
to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
such forward-looking statements involve risks and uncertainties,
including without limitation, continued acceptance of the
Company's products, increased levels of competition for the
Company, new products and technological changes, the Company's
dependence on third-party suppliers, and other risks detailed
from time to time in the Company's periodic reports filed
with the Securities and Exchange Commission.
For additional information, see www.coronadoindustries.com
Corporate Contact: Richard Smith, CEO, 480/837-6810
Investor Relations Contact: OTC Financial Network, Rick McCaffrey,
800/375-4678
rick@otcfn.com
Media Relations Contact: Silvana Rodriguez 561/750-9800 x
21
E-mail: srodriguez@transmediagroup.com
|
